NeuroOne Medical TechnologiesNMTC
NMTC
About: NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
Employees: 17
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
3,050% more call options, than puts
Call options by funds: $63K | Put options by funds: $2K
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
23% more capital invested
Capital invested by funds: $1.34M [Q4 2024] → $1.64M (+$304K) [Q1 2025]
1.0% more ownership
Funds ownership: 5.25% [Q4 2024] → 6.25% (+1.0%) [Q1 2025]
10% less funds holding
Funds holding: 20 [Q4 2024] → 18 (-2) [Q1 2025]
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$1.45
104%
upside
Avg. target
$1.45
104%
upside
High target
$1.45
104%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Ladenburg Thalmann Jeff Cohen | 104%upside $1.45 | Buy Initiated | 5 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System
Patient Treated with OneRF ® Ablation System Previously Experienced up to 10 Seizures a Day EDEN PRAIRIE, Minn., June 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that Clara—an early patient treated with the Company's patented OneRF® Ablation System—has successfully surpassed the one year milestone of being seizure free.
Neutral
GlobeNewsWire
1 month ago
NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary
EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has strengthened its management team with the appointment of Emily Johns as General Counsel and Corporate Secretary.
Neutral
GlobeNewsWire
1 month ago
NeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025
EDEN PRAIRIE, Minn., May 29, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the MedInvest MedTech, AI and Digital Health Conference taking place in San Francisco, CA on June 3-4, 2025.
Neutral
Seeking Alpha
1 month ago
NeuroOne Medical Technologies Corporation (NMTC) Q2 2025 Earnings Call Transcript
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q2 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Dave Rosa – CEO Ron McClurg – CFO Chris Volker - COO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Good day, ladies and gentlemen. Welcome to the Second Quarter of Fiscal Year 2025 Financial Results Conference Call for NeuroOne Medical Technologies Corporation.
Neutral
GlobeNewsWire
1 month ago
NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%
Filed 510(k)Submission with FDA for OneRF ® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule
Neutral
GlobeNewsWire
2 months ago
NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor
Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies
Neutral
Newsfile Corp
2 months ago
NeuroOne Medical Announces Participation in The D. Boral Capital Inaugural Global Conference
Eden Prairie, Minnesota--(Newsfile Corp. - May 5, 2025) - NeuroOne Medical (NASDAQ: NMTC), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.
Neutral
GlobeNewsWire
2 months ago
NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time
EDEN PRAIRIE, Minn., May 01, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal second quarter ended March 31, 2025, before market open on May 13, 2025.
Neutral
GlobeNewsWire
2 months ago
NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
Multi-Contact Probe Provides Alternative to Pharmaceutical and Invasive Surgical Treatments Submission Completed Earlier Than Anticipated EDEN PRAIRIE, Minn., April 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has filed its 510(k) submission to the FDA for trigeminal nerve ablation earlier than previous guidance.
Neutral
GlobeNewsWire
2 months ago
NeuroOne® Issues Letter to Shareholders
Company Now Fully Funded Through at least Fiscal 2026; Company Confirms No Material Impact from Global Tariffs EDEN PRAIRIE, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has issued a letter to shareholders from CEO, Dave Rosa.
Charts implemented using Lightweight Charts™